Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

209
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
209
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

789
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
789
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

246
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
246
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

758
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
758
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Modeling Partial and Total Support of Left Ventricular Assist Device for Discrete Hemodynamic Control Framework.

IEEE transactions on bio-medical engineering·2026
Same author

Renal Hemodynamic and Urinary Response to Baroreflex-Mediated Sympathetic Modulation: Insights from High-Resolution Arterial Impedance Analysis in Rats.

American journal of physiology. Regulatory, integrative and comparative physiology·2026
Same author

Positive End-expiratory Pressure Is Associated With Apparent Increases in Single-beat Left-ventricular End-systolic Elastance: Implications of Stroke Volume Sensitivity.

Journal of cardiothoracic and vascular anesthesia·2026
Same author

Self-folding graphene scaffolds with integrated electronics for cardiac tissue engineering.

Nanoscale·2026
Same author

Hemodynamic Implications After Left Ventricular Outflow Tract Obstruction Relief With Mavacamten.

JACC. Case reports·2026
Same author

Automated hemodynamic management system for the prevention of hypotension and cardiac output reduction during general anesthesia: preclinical experimental validation.

Journal of anesthesia·2026

関連する実験動画

Updated: Jan 14, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K

急性心不全における自律薬物療法の概念実証研究：離散的血行動態制御フレームワーク

Yasuyuki Kataoka, Kazunori Uemura, Mitsuji Sampei

    IEEE transactions on bio-medical engineering
    |January 12, 2026
    PubMed
    まとめ

    本研究では、血行動態を安定化させ、心筋酸素消費量を削減する急性心不全（AHF）向けの自律薬物療法システムを開発しました。このフレームワークは、治療精度を向上させ、クリティカルケア設定における臨床的意思決定を支援します。

    キーワード:
    急性心不全血行動態制御自律薬物療法クリティカルケア心血管生理学制御工学

    さらに関連する動画

    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
    10:05

    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

    Published on: July 7, 2016

    8.8K
    Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption
    12:43

    Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption

    Published on: August 16, 2016

    20.9K

    関連する実験動画

    Last Updated: Jan 14, 2026

    Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
    07:49

    Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

    Published on: July 21, 2023

    1.9K
    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
    10:05

    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

    Published on: July 7, 2016

    8.8K
    Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption
    12:43

    Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption

    Published on: August 16, 2016

    20.9K

    科学分野:

    • 心血管生理学
    • クリティカルケア医学
    • 制御システム工学

    背景:

    • 急性心不全（AHF）の管理は、心筋酸素消費量を最小限に抑えながら血行動態を安定化させる上で課題を提示します。
    • 複雑な心血管相互作用は、最適な患者転帰のために高度な治療戦略を必要とします。

    研究 の 目的:

    • AHFにおける自律薬物療法のための離散的血行動態制御フレームワークを開発すること。
    • AHF管理における制御汎用性と臨床的可能性を高めること。
    • 血行動態ターゲットを最適化し、心筋酸素消費量を最小限に抑えること。

    主な方法:

    • 心血管力学および薬剤応答の多入力多出力モデルを導出しました。
    • 血行動態ターゲットおよび薬剤投与を調節するための最適制御フレームワークを設計しました。
    • 投与量制限および禁忌を含む臨床的制約を組み込みました。
    • 心血管シミュレータを使用して制御性能を検証しました。

    主要な成果:

    • シミュレーションされたAHFシナリオにおいて、多次元的な血行動態調節を達成し、心筋酸素消費量を削減しました。
    • 到達可能な血行動態範囲を評価することにより、薬理学的に治療不可能な症例を特定することに成功しました。
    • 薬剤感受性および循環特性の患者間変動にもかかわらず、安定した性能を示しました。

    結論:

    • 開発されたシステムは、急性心不全管理のための医師支援ツールとして機能します。
    • 自律薬物療法の基盤を提供し、治療精度を向上させ、臨床医の負担を軽減します。
    • AHFにおけるクリティカルケアの進歩と薬物療法の最適化のためのスケーラブルなアプローチを提供します。